Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Doses Patients in China Trial of PD-L1 for Hepatitis B

publication date: Aug 17, 2020

Ascletis Pharma of Hangzhou has started dosing HBV patients in a China Phase IIa trial of its PD-L1 antibody. In 2019, Ascletis in-licensed China rights to the immunotherapy from Alphamab for patients with viral diseases. Alphamab, which continues to hold rights to the candidate for cancer, has tested the PD-L1 in more than 1,000 oncology patients. Ascletis agreed to pay Alphamab upfront and milestone payments, but it will be eligible to receive royalties on ex-China sales of the PD-L1 in viral diseases. More details....

Stock Symbol: (HK: 1672) (HK: 9966)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.